NewCa.com: Parc Jean-Drapeau Becomes the First Territory Outside
The Société du parc Jean-Drapeau (SPJD) is proud to announce that nearly 75% of the Park's territory* has been awarded the Ecological Area label by Ecocert
Source: newca.com
Ecocert Environment News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Ecocert Environment. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Ecocert Environment Today - Breaking & Trending Today
ImmunoPrecise Antibodies Ltd: Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration With Pierre Fabre
Multi-target research collaboration leverages ImmunoPrecise's powerful antibody discovery technologies with the long-standing expertise of Pierre Fabre in immuno-oncology IMMUNOPRECISE ANTIBODIES
Source: finanznachrichten.de
Le groupe Pierre Fabre représentera le Tarn au "Fabriqué en France" qui se tient à l'Elysée
Le groupe Pierre Fabre représentera le Tarn au "Fabriqué en France" qui se tient à l’Elysée La Crème d’Eau de Bleuet de la marque Klorane du Groupe Pierre Fabre a été sélectionnée pour représenter le Tarn à la Grande Exposition du Fabriqué en France au Palais de l’Elysée ce week-end. DDM - DIDIER POUYDEBAT à 07:10 La Crème d’Eau de Bleuet de la marque Klorane du Groupe Pierre Fabre a été sé...
Source: ladepeche.fr
License and Commercialization agreement between Pierre Fabre and ValenzaBio on an anti-IGF-1R antibody for the development of a novel treatment in Thyroid Eye Disease (TED)
(0) BESTHESDA, Maryland and CASTRES, France, April 8, 2021 /PRNewswire/ -- The US biopharmaceutical company ValenzaBio and the French pharmaceutical group Pierre Fabre announced today the signing of a license agreement of a preclinical insulin-like growth factor-1 receptor (IGF-1R) antagonist antibody, for the treatment of Thyroid Eye Disease (TED), an endocrine disease with unmet medical need. ValenzaBio received from Pierre Fabre the worldwide and exclusive rights to develop and commercialize, outside of oncology, the anti-IGF-1R antibody, discovered by Pierre Fabre at its Center of immunol...
Source: finanznachrichten.de